BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lacroix-Desmazes S, Voorberg J, Lillicrap D, Scott DW, Pratt KP. Tolerating Factor VIII: Recent Progress. Front Immunol 2019;10:2991. [PMID: 31998296 DOI: 10.3389/fimmu.2019.02991] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Croteau SE, Wang M, Wheeler AP. 2021 clinical trials update: Innovations in hemophilia therapy. Am J Hematol 2021;96:128-44. [PMID: 33064330 DOI: 10.1002/ajh.26018] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 21.0] [Reference Citation Analysis]
2 Bai H, Xue X, Tian L, Liu XT, Li Q. Case Report: Identification of a de novo Missense Mutation in the F8 Gene, p.(Phe690Leu)/c.2070C > A, Causing Hemophilia A: A Case Report. Front Genet 2020;11:589899. [PMID: 33747028 DOI: 10.3389/fgene.2020.589899] [Reference Citation Analysis]
3 Hoffmeister KM. Nonhuman sugars cause factor VIII troubles. Blood 2022;139:1262-3. [PMID: 35238885 DOI: 10.1182/blood.2021012121] [Reference Citation Analysis]
4 Pratt KP, Arruda VR, Lacroix-Desmazes S. Inhibitors-Recent insights. Haemophilia 2021;27 Suppl 3:28-36. [PMID: 32608138 DOI: 10.1111/hae.14077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Russell AL, Prince C, Lundgren TS, Knight KA, Denning G, Alexander JS, Zoine JT, Spencer HT, Chandrakasan S, Doering CB. Non-genotoxic conditioning facilitates hematopoietic stem cell gene therapy for hemophilia A using bioengineered factor VIII. Mol Ther Methods Clin Dev 2021;21:710-27. [PMID: 34141826 DOI: 10.1016/j.omtm.2021.04.016] [Reference Citation Analysis]
6 Srinivasan A, Herzog RW, Khan I, Sherman A, Bertolini T, Wynn T, Daniell H. Preclinical development of plant-based oral immune modulatory therapy for haemophilia B. Plant Biotechnol J 2021. [PMID: 33949086 DOI: 10.1111/pbi.13608] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Reipert BM, Gangadharan B, Hofbauer CJ, Berg V, Schweiger H, Bowen J, Blatny J, Fijnvandraat K, Mullins ES, Klintman J, Male C, McGuinn C, Meeks SL, Radulescu VC, Ragni MV, Recht M, Shapiro AD, Staber JM, Yaish HM, Santagostino E, Brown DL. The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development. Blood Adv 2020;4:5785-96. [PMID: 33232473 DOI: 10.1182/bloodadvances.2020002731] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
8 Karim AF, Soltis AR, Sukumar G, Königs C, Ewing NP, Dalgard CL, Wilkerson MD, Pratt KP. Hemophilia A Inhibitor Subjects Show Unique PBMC Gene Expression Profiles That Include Up-Regulated Innate Immune Modulators. Front Immunol 2020;11:1219. [PMID: 32595650 DOI: 10.3389/fimmu.2020.01219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Cohen S, Chung S. In vitro immunogenicity prediction: bridging between innate and adaptive immunity. Bioanalysis 2021;13:1071-81. [PMID: 34124935 DOI: 10.4155/bio-2021-0077] [Reference Citation Analysis]
10 Hassan S, Palla R, Valsecchi C, Garagiola I, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Karimi M, Gouw SC, Mannucci PM, Rosendaal FR, Peyvandi F; SIPPET study group. Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A. Haemophilia 2021;27:e441-9. [PMID: 33988289 DOI: 10.1111/hae.14325] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Schurgers E, Wraith DC. Induction of Tolerance to Therapeutic Proteins With Antigen-Processing Independent T Cell Epitopes: Controlling Immune Responses to Biologics. Front Immunol 2021;12:742695. [PMID: 34567009 DOI: 10.3389/fimmu.2021.742695] [Reference Citation Analysis]
12 Badescu MC, Badulescu OV, Butnariu LI, Floria M, Ciocoiu M, Costache I, Popescu D, Bratoiu I, Buliga-finis ON, Rezus C. Current Therapeutic Approach to Atrial Fibrillation in Patients with Congenital Hemophilia. JPM 2022;12:519. [DOI: 10.3390/jpm12040519] [Reference Citation Analysis]
13 Ronayne EK, Peters SC, Gish JS, Wilson C, Spencer HT, Doering CB, Lollar P, Spiegel PC Jr, Childers KC. Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor. Front Immunol 2021;12:697602. [PMID: 34177966 DOI: 10.3389/fimmu.2021.697602] [Reference Citation Analysis]
14 Winterling K, Martin WD, De Groot AS, Daufenbach J, Kistner S, Schüttrumpf J. Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach. J Thromb Haemost 2021;19:2161-70. [PMID: 34060724 DOI: 10.1111/jth.15413] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Khalilian S, Motovali-Bashi M, Rezaie H. Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients. Int J Mol Cell Med 2020;9:33-50. [PMID: 32832483 DOI: 10.22088/IJMCM.BUMS.9.1.33] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
16 Moorman CD, Sohn SJ, Phee H. Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy. Front Immunol 2021;12:657768. [PMID: 33854514 DOI: 10.3389/fimmu.2021.657768] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Li J, Chen J, Schroeder JA, Hu J, Williams CB, Shi Q. Platelet gene therapy induces robust immune tolerance even in a primed model via peripheral clonal deletion of antigen-specific T cells. Mol Ther Nucleic Acids 2021;23:719-30. [PMID: 33575117 DOI: 10.1016/j.omtn.2020.12.026] [Reference Citation Analysis]